

Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells.

Daniel Da Costa, Marine Turek, Daniel Felmlee, Erika Girardi, Sébastien Pfeffer, Gang Long, Ralf Bartenschlager, Mirjam Zeisel, Thomas Baumert

► **To cite this version:**

Daniel Da Costa, Marine Turek, Daniel Felmlee, Erika Girardi, Sébastien Pfeffer, et al.. Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells.: HCV life cycle in non-hepatic cells. Journal of Virology, American Society for Microbiology, 2012, epub ahead of print. <10.1128/JVI.01066-12>. <inserm-00734834>

HAL Id: inserm-00734834

<http://www.hal.inserm.fr/inserm-00734834>

Submitted on 24 Sep 2012

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Short-Form Paper

2 **Reconstitution of the entire hepatitis C virus life cycle in non-hepatic cells**

3 Daniel Da Costa^{1,2,*}, Marine Turek^{1,2,*}, Daniel J. Felmlee^{1,2,*}, Erika Girardi^{2,3},
4 Sébastien Pfeffer^{2,3}, Gang Long⁴, Ralf Bartenschlager⁴,
5 Mirjam B. Zeisel^{1,2,*#} and Thomas F. Baumert^{1,2,5,*#}

6 * these authors contributed equally to this work

7
8 ¹Inserm, U748, Strasbourg, France, ²Université de Strasbourg, Strasbourg, France,

9 ³Architecture et Réactivité de l'ARN, Institut de Biologie Moléculaire et Cellulaire du

10 CNRS, Strasbourg, France, ⁴Department of Molecular Virology, University of Heidelberg,

11 Heidelberg, Germany, ⁵Pôle Hépato-digestif, Hôpitaux Universitaires de Strasbourg,

12 Strasbourg, France

13

14 **Running title:** HCV life cycle in non-hepatic cells

15 **Abstract:** 71 words

16 **Main text:** 2235 words

17

18 **# Corresponding authors:** Thomas F. Baumert, MD, and Mirjam B. Zeisel, PhD,

19 PharmD, Inserm U748, Université de Strasbourg, 3 Rue Koeberlé, F-67000 Strasbourg,

20 France; Phone: (+33) 3 68 85 37 03, Fax: (+33) 3 68 85 37 24, e-mail:

21 Thomas.Baumert@unistra.fr, Mirjam.Zeisel@unistra.fr

22 **Author contribution:** MBZ and TFB designed and supervised research. DDC, MT, DJF,
23 EG, SP, GL, RB, MBZ and TFB performed research. DDC, MT, EG, SP, MBZ and TFB
24 analyzed data. RB provided important ideas for the initiation and execution of this study
25 and provided reagents. DDC, MT, MBZ, DJF and TFB wrote the manuscript. DDC, MT,
26 and DJF contributed equally to this work. MBZ and TFB contributed equally.

27

28 **Abbreviations:**

29 HCV, hepatitis C virus; HCVpp, retroviral HCV pseudo-particle; HCVcc, cell culture-
30 derived HCV; OCLN, occludin; CLDN1, claudin-1; SR-BI, scavenger receptor class B
31 type I; miR-122, microRNA-122; apoE, apolipoprotein E; EGFR, epidermal growth factor
32 receptor; VLDL, very-low-density lipoprotein.

33

34 **Abstract**

35 Hepatitis C virus (HCV) is a human hepatotropic virus, yet the relevant host factors
36 restricting HCV infection to hepatocytes are only partially understood. We demonstrate
37 that exogenous expression of defined host factors reconstituted the entire HCV life cycle
38 in human non-hepatic 293T cells. This study shows robust HCV entry, RNA replication,
39 and production of infectious virus in human non-hepatic cells, and highlights key host
40 factors required for liver tropism of HCV.

41

42 **Main Text**

43 Virus-host interactions that determine and restrict specific tissue and host tropisms
44 display complex evolutionary history and have significant consequences on the
45 pathogenesis of viral infection and human disease. Viral hepatitis is a major disease
46 burden. Indeed, infection of hepatocytes by a variety of hepatotropic viruses from
47 different orders and families can lead to tissue inflammation, fibrosis, and hepatocellular
48 carcinoma. Hepatitis C virus (HCV), a member of the family *Flaviviridae*, is a prime
49 example of a virus that causes chronic hepatitis worldwide. While HCV primarily infects
50 hepatocytes of humans and chimpanzees, the virus has been shown to enter neuronal
51 and endothelial cells of the blood-brain barrier. However, infection of these cells occurs
52 at a low level and production of infectious viruses is greatly diminished relative to
53 hepatically derived cells (9, 10). Unlike HCV, other members of the family *Flaviviridae*
54 have a much broader tissue and species tropism. For example Dengue virus infects and
55 replicates both in the midgut epithelia of *Aedes aegypti* mosquitoes, and in human
56 monocytes and hepatocytes (20, 25, 39). Moreover, a virus closely related to HCV was
57 recently identified from dogs' respiratory samples (18). A large panel of host factors
58 required for HCV has been identified so far (36). However, the key host factors
59 mediating liver tropism of the virus and allowing reconstitution of the viral life cycle in
60 human cells is still only partially understood.

61 Taking advantage of our current knowledge of host factors involved in HCV
62 infection, we sought to engineer a human kidney cell line (293T) to be capable of
63 sustaining the entire HCV life cycle. The aim was to define those host factors that are

64 necessary and sufficient for allowing the HCV life cycle, in order to understand the liver
65 tissue-specificity of HCV.

66 293T cells were obtained from ATCC and their identity was verified by genomic
67 profile comparison to the LGC Standards database by short tandem repeat profiling as
68 described (1) (Fig. 1A). In order to render them infectable by HCV, we used lentiviral
69 vectors to express the four principal HCV host entry factors: claudin-1 (CLDN1), CD81,
70 occludin (OCLN), and scavenger receptor class B type I (SR-BI) (2, 7, 34, 35) by using
71 previously described expression constructs and methods (3, 24). Four 293T stable cell
72 lines were selected to express either CLDN1 alone, CD81/OCLN with or without CLDN1,
73 or CLDN1/CD81/OCLN together with SR-BI (293T-4R). After verifying stable expression
74 of these proteins using receptor-specific antibodies (Fig. 1B), we infected these cells
75 with HCV pseudoparticles expressing the envelope glycoproteins of HCV genotype 1b
76 (HCVpp; HCV-J strain, described in (31)). While CLDN1 expression alone conferred
77 limited permissiveness for HCV infection as previously described (7), expression of all
78 four factors enhances HCV entry to a level that was around four-fold higher than
79 Huh7.5.1 cells, which is the liver-derived model hepatoma cell line for studying HCV
80 infection (Fig. 1C).

81 Genuine cell culture infection of HCV (HCVcc) was then investigated in 293T-4R
82 cells using a chimeric virus composed of two genotype 2a isolates (designated Jc1 (19,
83 32)) and engineered for Renilla luciferase expression (JcR2a; (38)). However, as shown
84 in Fig. 2A, overcoming the HCV entry block was not sufficient for robust viral RNA
85 replication in 293T cells.

86 Several studies have shown that microRNA (miR)-122 is a liver-specific host
87 factor critical for HCV replication (5, 16, 17, 28). Since Northern blot analyses
88 demonstrated non-detectable miR-122 expression in 293T-4R cells (Fig. 2C), we
89 investigated whether exogenous miR-122 expression reconstituted viral RNA replication.
90 Indeed, stable expression of this factor, by using miR-122 encoding lentiviruses in the
91 293T-4R line, conferred the cells permissive for bona fide HCVcc infection, with
92 replication to comparable levels as Huh7.5.1 cells as assessed by luciferase reporter
93 activity (Fig. 2B). Further confirmation of genuine infection was garnered by observing
94 similar infectivity (TCID₅₀) with HCVcc (Jc1) without a reporter gene, by detecting
95 expression of viral protein NS5A (Fig. 2B). We verified expression of miR-122 in
96 transduced 293T-4R/miR122 cells, and the level was comparable to that of Huh7.5.1
97 cells as assessed by Northern blot (Fig. 2C), and the cell proliferation rate of the
98 different cell lines was similar (data not shown). Kinetics of HCV replication in 293T-
99 4R/miR122 cells matched those of Huh7.5.1 cells, suggesting that aside from miR-122,
100 cell factors present in human liver- and kidney-derived cells are equally efficient for
101 replication as assayed by luciferase reporter gene expression (Fig. 2D). Expression of
102 viral proteins in infected cells was further confirmed using HCV core-specific
103 immunofluorescence (Fig. 2E) and flow cytometry (data not shown).

104 To further confirm whether viral entry and replication in stably transduced 293T
105 cells is mediated by the same host and virus factors as in human Huh7.5.1 hepatoma
106 cells, we used well-characterized entry and replication inhibitors. Antibodies directed
107 against the HCV entry factors CD81, CLDN1, and SR-BI (JS-81, BD Biosciences, (11),
108 Zahid et al., unpublished, respectively) were effective in inhibiting infection (Fig. 2F).

109 Moreover, both a polyclonal serum recognizing apolipoprotein E (apoE) (29), and a
110 monoclonal antibody recognizing the LDL receptor binding domain of apoE (37)
111 effectively neutralized HCV infection of 293T-4R/miR122 cells (Fig. 2F). The same was
112 true for the recently identified HCV entry inhibitor, erlotinib, which targets the kinase
113 activity of the host entry regulatory protein, epidermal growth factor receptor (EGFR)
114 (Fig. 2F) (24). Likewise, well characterized inhibitors of HCV NS3 protease or
115 polymerase, telaprevir (VX950) and mericitabine (R7128), impaired HCV replication in
116 293T-4R/miR122 cells (Fig. 2F). These data demonstrate that HCVcc RNA replication in
117 kidney-derived 293T-4R/miR122 cells is efficient, and dependent on similar mechanisms
118 as in liver-derived Huh7.5.1 cells.

119 Despite efficient entry and RNA replication of 293T-4R/miR122 cells infected with
120 recombinant HCVcc, these cells did not release infectious virions, suggesting that
121 kidney-derived cells lack factors required for viral assembly and release. Therefore, we
122 aimed to reconstitute virus production by expression of HCV assembly factors. HCV
123 production shares factors involved in very-low-density lipoprotein (VLDL) assembly, a
124 process that occurs exclusively in hepatocytes (13, 14, 27). While the necessity of
125 apolipoprotein B (apoB) in HCV production is controversial (15), apoE is known to be
126 critical, and is incorporated into the virion (26). We therefore expressed the most
127 common isoform of apoE (apoE3) in 293T-4R/miR122 cells by using a lentiviral vector
128 encoding human apoE3 as described previously (23), and confirmed its expression by
129 flow cytometry using an apoE-specific antibody (Fig. 3A). We then infected 293T-
130 4R/miR122/apoE cells. Subsequently, the production and release of viral particles was
131 assessed by incubating naïve Huh7.5.1 cells with the supernatants from these cells.

132 Indeed, 293T-4R/miR122/apoE released infectious HCV particles as shown by a marked
133 and highly significant increase in infectivity (as assessed by luciferase activity of JcR2a
134 virus and TCID₅₀ of Jc1 virus without a reporter gene) of the supernatant compared to
135 the supernatant of 293T-4R/miR122 cells without apoE expression (Fig. 3B). Although
136 the production of infectious particles was lower than in Huh7.5.1 cells studied in side-by-
137 side experiments, these data indicate that apoE is a key factor for virus production in
138 reconstituting the viral life cycle in non-hepatic cells. This diminished HCV production
139 was not due to diminished replication levels as apoE transduced cells had similar HCV
140 replication levels to 293T-4R/miR122 cells prior to apoE expression (data not shown).
141 To test if HCV produced by these cells is reliant only on human apoE3 isoform or could
142 use other forms of apoE, we similarly transduced human apoE2 and apoE4 isoforms, as
143 well as murine apoE (Fig. 3C). Viruses produced from 293T cells expressing these apoE
144 isoforms and the mouse ortholog had similar infectivity compared to human apoE3
145 isoform (Fig. 3D).

146 Focusing on the most common apoE isoform (apoE3), we further characterized
147 the kinetics and attributes of these viruses. First, we confirmed that HCV particles from
148 engineered 293T cells could establish infection by monitoring the increase in HCV
149 genomes over time in Huh7.5.1 target cells after exposure to the supernatant of HCVcc-
150 infected 293T-4R/miR122/apoE cells (Fig. 4A). Next, we characterized the kinetics of
151 HCV RNA production from infected 293T-4R/miR122/apoE cells by measuring HCV
152 RNA in the media at serial time points following infection (Fig. 4B). Interestingly, the
153 levels of HCV RNA released into the culture media of 293T-4R/miR122/apoE cells was
154 similar to levels of HCV RNA in the media of Huh7.5.1 cells after 72h, whereas cells that

155 were not transduced with apoE released minimal amounts of HCV RNA, likely due to
156 previously reported non-specific release of HCV RNA during replication (Fig. 4B)(33).
157 These data suggest that the specific infectivity differs between virus produced from
158 Huh7.5.1 cells and 293T cells engineered to express essential host factors. An
159 estimation of the specific infectivity of the released viruses (TCID₅₀/HCV RNA genomes)
160 revealed approximately a 30-fold difference between the differently derived viruses
161 (1/900 for Huh7.5.1-derived virus and 1/26,000 for 293T-4R/miR122/apoE-derived
162 virus). It should be noted that HCV particles produced from 293T-4R/miR122/apoE cells
163 proved to have a similar route of infection to hepatically-derived HCVcc, in that entry into
164 Huh7.5.1 cells was neutralized by well-characterized HCV entry inhibitors including
165 CD81-, SR-BI-, CLDN1-, apoE-specific antibodies, and erlotinib (Fig. 4C). Fractionating
166 the virus by iodixanol density gradients revealed that the infectious virions produced
167 from 293T-4R/miR122/apoE cells have similar buoyant density as those from Huh7.5.1
168 cells (Fig. 4D).

169 The data presented here demonstrate that trans-expression of OCLN, CD81,
170 CLDN1, SR-BI, miR-122, and apoE endow 293T human kidney-derived cells with the
171 capacity to support the complete HCV life cycle. Expression of four principal entry
172 factors and miR-122 generated cells with higher entry and similar replication kinetics as
173 the extensively optimized Huh7.5.1 cells (4, 41). It should be noted in this context, that
174 the recently identified entry factor EGFR is also expressed in 293T cells (data not
175 shown, 24, 40). We confirmed that expression of CLDN1 alone appears to be sufficient
176 for infection of 293T cells (7), and expand these findings in that high-level expression of
177 the four canonical HCV entry factors make previously impenetrable cells four-fold more

178 permissive than Huh7.5.1 cells. These observations were confirmed by HCVcc infection
179 of 293T cells engineered to express miR-122 in addition to variable sets of entry factors
180 (data not shown). While the present study focused on engineering a human cell line for
181 infection, it has been demonstrated that concomitant high level expression of the four
182 human entry factors is required for robust entry of mouse hepatocytes *in vivo* (6). Since
183 none of the identified entry factors are exclusively expressed in the liver, it is likely that
184 the combined expression of these host factors at substantial levels allows the virus to
185 productively infect the human liver, rather than a single liver-specific entry factor
186 restricting HCV infection.

187 Investigators have shown that miR-122 expression increases HCV replication in
188 mouse embryonic fibroblasts and other hepatoma cell lines such as HepG2 cells (21, 17,
189 28). Furthermore, HEK-293 cells modified to express miR-122 are capable of sustaining
190 selectable HCV subgenomic replicons, although expression of mutated miR-122, at sites
191 required for HCV RNA binding, can also sustain these replicons (5). We demonstrate
192 here *de novo* replication following an infection event of a non-hepatic cell line
193 engineered to express HCV host factors. Our data also demonstrate that there is no
194 restrictive factor of HCV entry and viral RNA replication that is present in 293T cells.
195 HCV entry and replication in human blood brain barrier endothelial and neuronal cells
196 have been described (9, 10). In contrast to the kidney-derived cells described here, HCV
197 replication in blood brain barrier endothelial cells occurred via a miR-122 independent
198 mechanism, yet at a diminished level (9). Thus, the cell lines developed in this study
199 may be useful as a tool to further understand the molecular mechanisms of extra-hepatic
200 infection.

201 The production of HCV from 293T-4R/miR122/apoE cells was diminished relative
202 to Huh7.5.1 cells, but markedly and significantly higher than in cells without apoE
203 expression. This demonstrates that apart from apoE, all the other factors necessary for
204 the production of infectious particles are present in 293T cells, yet additional host factors
205 may increase efficient production levels. The cell line generated in this study is likely to
206 allow further discovery of the minimal set of host factors required for robust viral
207 production. Additional relevant factors enhancing viral production may be apoB (27),
208 DGAT1 (13), or microsomal triglyceride transfer protein (MTP) (12, 14). Notably, apoE
209 has recently been demonstrated to be essential for virus production; apoE-deficient
210 mouse hepatocytes with trans-expression of HCV RNA and proteins along with apoE are
211 able to produce high levels of infectious virions (23).

212 In summary, this study demonstrates that a small set of defined host factors is
213 sufficient to reconstitute the complete viral life cycle in non-hepatic cells. These results
214 advance our knowledge on tissue-specific factors for HCV infection and provide novel
215 tools to elucidate host and restriction factors for the HCV life cycle.

216 **Acknowledgments**

217 This work was supported by the European Union (ERC-2008-AdG-233130-HEPCENT,
218 INTERREG-IV-Rhin Supérieur-FEDER-Hepato-Regio-Net 2009), an EASL fellowship to
219 D.J.F., ANRS (2011/132), Laboratoire d'Excellence HEPSYS (Investissement d'Avenir ;
220 ANR-10-LAB-28), an ANRS fellowship to E.G., Inserm, CNRS and Université de
221 Strasbourg. We thank T. Pietschmann (Division of Experimental Virology, TWINCORE,
222 Hannover, Germany) for providing the lentiviral vectors encoding HCV entry factors, F.-

223 L. Cosset for providing plasmids for the production of HCVpp, D. Trono (Ecole
224 Polytechnique Fédérale de Lausanne, Switzerland) for pWPI plasmid, R. Milne for
225 monoclonal apoE antibody, M. Harris for HCV NS5A antibody used for
226 immunohistochemistry, and F. Chisari for providing Huh7.5.1 cells. We acknowledge
227 Sarah Durand (Inserm U748, Strasbourg) and Charlotte Bach (Inserm U748,
228 Strasbourg) for excellent technical work. We are thankful to Heidi Barth (Inserm U748,
229 Strasbourg) and Catherine Schuster (Inserm U748, Strasbourg) for helpful discussions.

230

231 **References**

- 232 1. American Type Culture Collection Standards Development Organization
233 Workgroup ASN-0002. 2010. Cell line misidentification: the beginning of the end.
234 Nat Rev Cancer 10:441-8.
- 235 2. Bartosch, B., A. Vitelli, C. Granier, C. Goujon, J. Dubuisson, S. Pascale, E.
236 Scarselli, R. Cortese, A. Nicosia, and F. L. Cosset. 2003. Cell entry of hepatitis C
237 virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-
238 B1 scavenger receptor. J Biol Chem 278:41624-30.
- 239 3. Bitzegeio, J., D. Bankwitz, K. Hueging, S. Haid, C. Brohm, M. B. Zeisel, E.
240 Herrmann, M. Iken, M. Ott, T. F. Baumert, and T. Pietschmann. 2010. Adaptation
241 of hepatitis C virus to mouse CD81 permits infection of mouse cells in the
242 absence of human entry factors. PLoS Pathog 6:e1000978.
- 243 4. Blight, K. J., J. A. McKeating, and C. M. Rice. 2002. Highly permissive cell lines
244 for subgenomic and genomic hepatitis C virus RNA replication. J Virol 76:13001-
245 14.
- 246 5. Chang, J., J. T. Guo, D. Jiang, H. Guo, J. M. Taylor, and T. M. Block. 2008. Liver-
247 specific microRNA miR-122 enhances the replication of hepatitis C virus in
248 nonhepatic cells. J Virol 82:8215-23.
- 249 6. Dorner, M., J. A. Horwitz, J. B. Robbins, W. T. Barry, Q. Feng, K. Mu, C. T.
250 Jones, J. W. Schoggins, M. T. Catanese, D. R. Burton, M. Law, C. M. Rice, and
251 A. Ploss. 2011. A genetically humanized mouse model for hepatitis C virus
252 infection. Nature 474:208-11.

- 253 7. Evans, M. J., T. von Hahn, D. M. Tscherne, A. J. Syder, M. Panis, B. Wolk, T.
254 Hatzioannou, J. A. McKeating, P. D. Bieniasz, and C. M. Rice. 2007. Claudin-1 is
255 a hepatitis C virus co-receptor required for a late step in entry. *Nature* 446:801-5.
- 256 8. Fafi-Kremer, S., I. Fofana, E. Soulier, P. Carolla, P. Meuleman, G. Leroux-Roels,
257 A. H. Patel, F. L. Cosset, P. Pessaux, M. Doffoel, P. Wolf, F. Stoll-Keller, and T.
258 F. Baumert. 2010. Viral entry and escape from antibody-mediated neutralization
259 influence hepatitis C virus reinfection in liver transplantation. *J Exp Med*
260 207:2019-31.
- 261 9. Fletcher, N. F., G. K. Wilson, J. Murray, K. Hu, A. Lewis, G. M. Reynolds, Z.
262 Stamataki, L. W. Meredith, I. A. Rowe, G. Luo, M. A. Lopez-Ramirez, T. F.
263 Baumert, B. Weksler, P. O. Couraud, K. S. Kim, I. A. Romero, C. Jopling, S.
264 Morgello, P. Balfe, and J. A. McKeating. 2012. Hepatitis C virus infects the
265 endothelial cells of the blood-brain barrier. *Gastroenterology* 142:634-643 e6.
- 266 10. Fletcher, N. F., J. P. Yang, M. J. Farquhar, K. Hu, C. Davis, Q. He, K. Dowd, S.
267 C. Ray, S. E. Krieger, J. Neyts, T. F. Baumert, P. Balfe, J. A. McKeating, and F.
268 Wong-Staal. 2010. Hepatitis C virus infection of neuroepithelioma cell lines.
269 *Gastroenterology* 139:1365-74.
- 270 11. Fofana, I., S. E. Krieger, F. Grunert, S. Glaben, F. Xiao, S. Fafi-Kremer, E.
271 Soulier, C. Royer, C. Thumann, C. J. Mee, J. A. McKeating, T. Dragic, P.
272 Pessaux, F. Stoll-Keller, C. Schuster, J. Thompson, and T. F. Baumert. 2010.
273 Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary
274 human hepatocytes. *Gastroenterology* 139:953-64, 964 e1-4.

- 275 12. Gastaminza, P., G. Cheng, S. Wieland, J. Zhong, W. Liao, and F. V. Chisari.
276 2008. Cellular determinants of hepatitis C virus assembly, maturation,
277 degradation, and secretion. *J Virol* 82:2120-9.
- 278 13. Herker, E., C. Harris, C. Hernandez, A. Carpentier, K. Kaehlcke, A. R.
279 Rosenberg, R. V. Farese, Jr., and M. Ott. 2010. Efficient hepatitis C virus particle
280 formation requires diacylglycerol acyltransferase-1. *Nat Med* 16:1295-8.
- 281 14. Huang, H., F. Sun, D. M. Owen, W. Li, Y. Chen, M. Gale, Jr., and J. Ye. 2007.
282 Hepatitis C virus production by human hepatocytes dependent on assembly and
283 secretion of very low-density lipoproteins. *Proc Natl Acad Sci U S A* 104:5848-53.
- 284 15. Jiang, J., and G. Luo. 2009. Apolipoprotein E but not B is required for the
285 formation of infectious hepatitis C virus particles. *J Virol* 83:12680-91.
- 286 16. Jopling, C. L., M. Yi, A. M. Lancaster, S. M. Lemon, and P. Sarnow. 2005.
287 Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.
288 *Science* 309:1577-81.
- 289 17. Kambara, H., T. Fukuhara, M. Shiokawa, C. Ono, Y. Ohara, W. Kamitani, and Y.
290 Matsuura. 2012. Establishment of a novel permissive cell line for the propagation
291 of hepatitis C virus by expression of microRNA miR122. *J Virol* 86:1382-93.
- 292 18. Kapoor, A., P. Simmonds, G. Gerold, N. Qaisar, K. Jain, J. A. Henriquez, C. Firth,
293 D. L. Hirschberg, C. M. Rice, S. Shields, and W. I. Lipkin. 2011. Characterization
294 of a canine homolog of hepatitis C virus. *Proc Natl Acad Sci U S A* 108:11608-13.
- 295 19. Koutsoudakis, G., A. Kaul, E. Steinmann, S. Kallis, V. Lohmann, T. Pietschmann,
296 and R. Bartenschlager. 2006. Characterization of the early steps of hepatitis C
297 virus infection by using luciferase reporter viruses. *J Virol* 80:5308-20.

- 298 20. Leake, C. J. 1992. Arbovirus-mosquito interactions and vector specificity.
299 Parasitol Today 8:123-8.
- 300 21. Lin, L. T., R. S. Noyce, T. N. Pham, J. A. Wilson, G. R. Sisson, T. I. Michalak, K.
301 L. Mossman, and C. D. Richardson. 2010. Replication of subgenomic hepatitis C
302 virus replicons in mouse fibroblasts is facilitated by deletion of interferon
303 regulatory factor 3 and expression of liver-specific microRNA 122. J Virol
304 84:9170-80.
- 305 22. Lindenbach, B. D., M. J. Evans, A. J. Syder, B. Wolk, T. L. Tellinghuisen, C. C.
306 Liu, T. Maruyama, R. O. Hynes, D. R. Burton, J. A. McKeating, and C. M. Rice.
307 2005. Complete replication of hepatitis C virus in cell culture. Science 309:623-6.
- 308 23. Long, G., M. S. Hiet, M. P. Windisch, J. Y. Lee, V. Lohmann, and R.
309 Bartenschlager. 2011. Mouse hepatic cells support assembly of infectious
310 hepatitis C virus particles. Gastroenterology 141:1057-66.
- 311 24. Lupberger, J., M. B. Zeisel, F. Xiao, C. Thumann, I. Fofana, L. Zona, C. Davis, C.
312 J. Mee, M. Turek, S. Gorke, C. Royer, B. Fischer, M. N. Zahid, D. Lavillette, J.
313 Fresquet, F. L. Cosset, S. M. Rothenberg, T. Pietschmann, A. H. Patel, P.
314 Pessaux, M. Doffoel, W. Raffelsberger, O. Poch, J. A. McKeating, L. Brino, and T.
315 F. Baumert. 2011. EGFR and EphA2 are host factors for hepatitis C virus entry
316 and possible targets for antiviral therapy. Nat Med 17:589-95.
- 317 25. Martina, B. E., P. Koraka, and A. D. Osterhaus. 2009. Dengue virus
318 pathogenesis: an integrated view. Clin Microbiol Rev 22:564-81.
- 319 26. Merz, A., G. Long, M. S. Hiet, B. Brugger, P. Chlanda, P. Andre, F. Wieland, J.
320 Krijnse-Locker, and R. Bartenschlager. 2011. Biochemical and morphological

- 321 properties of hepatitis C virus particles and determination of their lipidome. *J Biol*
322 *Chem* 286:3018-32.
- 323 27. Nahmias, Y., J. Goldwasser, M. Casali, D. van Poll, T. Wakita, R. T. Chung, and
324 M. L. Yarmush. 2008. Apolipoprotein B-dependent hepatitis C virus secretion is
325 inhibited by the grapefruit flavonoid naringenin. *Hepatology* 47:1437-45.
- 326 28. Narbus, C. M., B. Israelow, M. Sourisseau, M. L. Michta, S. E. Hopcraft, G. M.
327 Zeiner, and M. J. Evans. 2011. HepG2 cells expressing microRNA miR-122
328 support the entire hepatitis C virus life cycle. *J Virol* 85:12087-92.
- 329 29. Owen, D. M., H. Huang, J. Ye, and M. Gale, Jr. 2009. Apolipoprotein E on
330 hepatitis C virion facilitates infection through interaction with low-density
331 lipoprotein receptor. *Virology* 394:99-108.
- 332 30. Pall, G. S., and A. J. Hamilton. 2008. Improved northern blot method for
333 enhanced detection of small RNA. *Nat Protoc* 3:1077-84.
- 334 31. Pestka, J. M., M. B. Zeisel, E. Blaser, P. Schurmann, B. Bartosch, F. L. Cosset,
335 A. H. Patel, H. Meisel, J. Baumert, S. Viazov, K. Rispeter, H. E. Blum, M.
336 Roggendorf, and T. F. Baumert. 2007. Rapid induction of virus-neutralizing
337 antibodies and viral clearance in a single-source outbreak of hepatitis C. *Proc*
338 *Natl Acad Sci U S A* 104:6025-30.
- 339 32. Pietschmann, T., A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E.
340 Steinmann, K. Abid, F. Negro, M. Dreux, F. L. Cosset, and R. Bartenschlager.
341 2006. Construction and characterization of infectious intragenotypic and
342 intergenotypic hepatitis C virus chimeras. *Proc Natl Acad Sci U S A* 103:7408-13.

- 343 33. Pietschmann, T., V. Lohmann, A. Kaul, N. Krieger, G. Rinck, G. Rutter, D. Strand,
344 and R. Bartenschlager. 2002. Persistent and transient replication of full-length
345 hepatitis C virus genomes in cell culture. *J Virol* 76:4008-21.
- 346 34. Pileri, P., Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, R. Petracca, A. J.
347 Weiner, M. Houghton, D. Rosa, G. Grandi, and S. Abrignani. 1998. Binding of
348 hepatitis C virus to CD81. *Science* 282:938-41.
- 349 35. Ploss, A., M. J. Evans, V. A. Gaysinskaya, M. Panis, H. You, Y. P. de Jong, and
350 C. M. Rice. 2009. Human occludin is a hepatitis C virus entry factor required for
351 infection of mouse cells. *Nature* 457:882-6.
- 352 36. Ploss, A., and C. M. Rice. 2009. Towards a small animal model for hepatitis C.
353 *EMBO Rep* 10:1220-7.
- 354 37. Raffai, R., R. Maurice, K. Weisgraber, T. Innerarity, X. Wang, R. MacKenzie, T.
355 Hirama, D. Watson, E. Rassart, and R. Milne. 1995. Molecular characterization of
356 two monoclonal antibodies specific for the LDL receptor-binding site of human
357 apolipoprotein E. *J Lipid Res* 36:1905-18.
- 358 38. Reiss, S., I. Rebhan, P. Backes, I. Romero-Brey, H. Erfle, P. Matula, L. Kaderali,
359 M. Poenisch, H. Blankenburg, M. S. Hiet, T. Longerich, S. Diehl, F. Ramirez, T.
360 Balla, K. Rohr, A. Kaul, S. Buhler, R. Pepperkok, T. Lengauer, M. Albrecht, R.
361 Eils, P. Schirmacher, V. Lohmann, and R. Bartenschlager. 2011. Recruitment and
362 activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of
363 the membranous replication compartment. *Cell Host Microbe* 9:32-45.
- 364 39. Salazar, M. I., J. H. Richardson, I. Sanchez-Vargas, K. E. Olson, and B. J. Beaty.
365 2007. Dengue virus type 2: replication and tropisms in orally infected *Aedes*
366 *aegypti* mosquitoes. *BMC Microbiol* 7:9.

- 367 40. Yan, W., and R. Shao. 2006. Transduction of a mesenchyme-specific gene
368 periostin into 293T cells induces cell invasive activity through epithelial-
369 mesenchymal transformation. *J Biol Chem* 281:19700-8.
- 370 41. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F.
371 Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C
372 virus infection in vitro. *Proc Natl Acad Sci U S A* 102:9294-9.
- 373

374 **Figure Legends**

375 **Figure 1. Expression of four HCV entry factors renders 293T cells highly**
376 **permissive to HCVpp entry.** (A) Short tandem repeat (STR) profile of the 293T cells
377 used in this study (Cell line authentication, LGC Standards) was performed as described
378 previously (1). The names of tested loci are indicated in bold and peak positions from
379 STR profile of 293T cells were compared to LGC Standards database. (B) 293T cells
380 (cultured in DMEM high glucose, Life Tech) were transduced with lentiviruses (as
381 described in (3)) to express given HCV entry factors. After transduction, cells were
382 selected with blasticidin (12 µg/ml) for 2 weeks. Blasticidin-resistant cells were assessed
383 by flow cytometry using monoclonal antibodies (CLDN1 (11), OCLN (Cat.# 33-1500
384 Invitrogen), SR-BI (Zahid et al., submitted manuscript)) recognizing indicated entry
385 factors. Entry factor transduced cells (dark grey histograms) were compared to naïve
386 293T cells (light grey histograms) and isotype control antibody (Cat.# 10400C, Life
387 Technologies, white dashed histograms). X axis: fluorescence intensity, Y axis: number
388 of events. (C) Transduced 293T cells were assessed for HCVpp (genotype 1b; HCV-J
389 strain; produced as described in (31)) entry by determining luciferase activity 72h post-
390 infection as previously described (35). Results were first normalized to vesicular
391 stomatitis virus pseudoparticle entry (VSV-Gpp; produced as described in (8)), and then
392 compared to Huh7.5.1 cells (cultured as described in (41)). Results are expressed as
393 means +/- SD of percentage HCVpp entry relative to entry into Huh7.5.1 cells from three
394 independent experiments performed in triplicate, and 100% relative infectivity is
395 represented by a solid line. Statistical analysis for entry factor expressing cells relative to
396 naïve 293T cells was performed using the Student's *t* test, *P<0.05.

397

398 **Figure 2. 293T-4R cells support robust HCV infection upon miR-122 expression.**

399 (A) Stable 293T-4R cells described in Fig. 1 were challenged with HCVcc (JcR2a;
400 produced as described in (38)) or were mock infected and luciferase activity was
401 assessed 72h post-infection as described previously (38). Results are expressed as
402 means +/- SD of relative light units (RLU) from three independent experiments
403 performed in triplicate. (B) 293T-4R cells were stably transduced using miR-122
404 encoding lentiviruses (Cat.# mh15049, ABM Good) and puromycin (2,5 µg/ml) resistant
405 cells were selected over 2 weeks. 293T-4R/miR122 cells and Huh7.5.1 cells were then
406 infected with HCVcc or mock infected for 6h. Infection was assayed by monitoring
407 luciferase activity 72h post-infection. Results are expressed as means +/- SD of relative
408 light units (RLU) from three independent experiments performed in triplicate. Jc1, an
409 HCVcc without a luciferase reporter (32) was likewise used to infect Huh7.5.1 and 293T-
410 4R/miR122 cells and its infectivity was assessed by limiting-dilution assay (TCID₅₀) by
411 detecting viral protein NS5A using immunohistochemistry, represented as grey bars
412 (22). Results are expressed as means +/- SD of TCID₅₀/ml from three independent
413 experiments. (C) Northern blots of miR-122 and miR-16, and U6 RNA as a loading
414 control, extracted from 293T-4R, 293T-4R stably expressing miR-122, and Huh7.5.1
415 cells as positive control. Northern blots using a miR-122-specific probe were performed
416 as described previously (30). Oligonucleotide lengths (nt) are indicated on the left of
417 each blot. (D) 293T-4R, 293T-4R/miR122 and Huh7.5.1 cells were incubated side-by-
418 side with HCVcc (JcR2a) and luciferase activity was monitored every 24h over a 72 h
419 period. Results are expressed as means +/- SD of relative light units (RLU) of three
420 independent experiments performed in triplicate. (E) Huh7.5.1, 293T-4R, and 293T-

421 4R/miR122 cells were infected for 72 h and HCV core protein (core antibody C7-50,
422 Thermo Scientific,), or non-specific IgG, as a control (Cat.# 10400C, Life Technologies)
423 were observed by immunofluorescence; nuclei were stained using DAPI. (F) 293T-
424 4R/miR122 cells were pre-incubated for 1h at 37°C with the indicated entry inhibitors,
425 antivirals or controls (monoclonal antibodies (mAb), anti-CD81 (JS81, BD Biosciences),
426 anti-CLDN1 (11), anti-SR-BI (Zahid et al. submitted manuscript), polyclonal (pAb) anti-
427 apoE (Cat #178479, Calbiochem), anti-apoE mAb was described in (37), 20 µg/ml,
428 erlotinib: 10 µM (Cat.# E-4997, LC Laboratories), protease inhibitor telaprevir VX950: 1
429 µM; polymerase inhibitor mericitabine R7128: 1 µM; both synthesized by Acme
430 Bioscience Inc. , DMSO: 0.7%, and then infected with HCVcc (JcR2a) in the presence of
431 given entry inhibitors or antivirals. Cell lysates were assessed for luciferase activity 72h
432 post-infection. Results are expressed as means +/- SEM of percentage HCVcc infection
433 compared to controls, from three independent experiments performed in triplicate, and
434 100% relative infectivity is represented by a solid line. In panels A, B, and D, detection
435 limits are represented by dashed lines. Statistical analysis relative to control was
436 performed using the Student's *t* test, *P<0.05.

437
438 **Figure 3. Infectious HCV particles are released from 293T-4R/miR122 cells upon**
439 **apoE expression.** (A) 293T-4R/miR122 cells were transduced with an apoE3 encoding
440 lentiviral vector described in (23). 72h post-transduction, cells that were or were not
441 transduced were stained for flow cytometry analysis. ApoE expression was analyzed
442 using a specific apoE antibody (clone D6E10, Cat.# ab1906, Abcam, untransduced cells
443 are represented as light grey histogram and transduced cells are shown as dark grey
444 histogram) and an isotype antibody (Cat.# 10400C, Life Technologies) was used as

445 control (white dashed histograms). Huh7.5.1 cells were used for control of apoE
446 expression and PBS is presented as control of the isotype antibody (thick black
447 histogram). (B) Transduced 293T-4R/miR122/apoE cells were infected with HCVcc
448 (JcR2a, or Jc1). 6h post-infection, cells were washed three times with PBS, and fresh
449 culture medium was added. 72h post-infection, media from infected cells was passaged
450 onto naïve Huh7.5.1 cells. Cell lysates of JcR2a infected cells were assessed for
451 luciferase activity 72h post-infection. Results are expressed as means +/- SD of relative
452 light units (RLU) of three independent experiments performed in triplicate. The detection
453 limit is represented by a dashed line. The infectivities of Jc1 derived from Huh7.5.1 or
454 293T-4R/miR122/apoE infected cells were assessed by limiting-dilution assay (TCID₅₀)
455 by detecting NS5A by immunohistochemistry, represented as grey bars. Results are
456 expressed as means +/- SD of TCID₅₀/ml from three independent experiments. #
457 represents below detectable levels. Statistical analysis relative to the control was
458 performed using the Student's *t* test, *P<0.05. (C) 293T-4R/miR122 cells were
459 transduced with indicated apoE isoform-encoding lentiviral vectors (24), or mock
460 transduced (Control). 72h post-transduction, cells were either lysed or seeded for
461 HCVcc infection. Cell lysates were assessed for apoE expression by Western blot either
462 by using apoE antibody (clone D6E10, Cat.# ab1906, Abcam) for human apoE (h-apoE)
463 expression or using a mouse apoE specific antibody for mouse apoE (m-apoE)
464 expression (Cat# ab20874, Abcam). Huh7.5.1 and primary mouse hepatocytes (PMH)
465 were used as controls for human and mouse apoE expression, respectively. (D) The
466 different apoE isoform-expressing 293T-derived cells were assessed for their capacity to
467 produce infectious virus by infecting them with HCVcc (JcR2a) and 72h post-infection,
468 supernatants of infected 293T-derived cells were passaged onto naïve Huh7.5.1 cells.

469 72h after initiating this infection, Huh7.5.1 cells were lysed and luciferase activity
470 assessed. Results are expressed as means +/- SD of relative light units (RLU) from a
471 representative experiment performed in triplicate. The dashed line represents the
472 detection limit.

473
474 **Figure 4. Characterization of HCVcc derived from 293T-4R/miR122/apoE cells (A)**

475 Culture media from Jc1-infected 293T-4R/miR122, 293T-4R/miR122/apoE, and
476 Huh7.5.1 cells were passaged onto naïve Huh7.5.1 target cells. Total RNA from these
477 Huh7.5.1 target cells was extracted at indicated time points and HCV RNA was
478 quantitated by RT-qPCR as described (11). Values were normalized to the internal
479 control gene GAPDH and are represented as HCV RNA to GAPDH RNA ratio. Results
480 are expressed as means +/- SD from an experiment performed in quadruplicate. (B)
481 HCV RNA production was measured by infecting 293T-4R/miR122, 293T-
482 4R/miR122/apoE and Huh7.5.1 cells side-by-side with HCVcc (Jc1). RNA from
483 supernatants of infected cells was extracted at indicated time points and HCV RNA
484 quantitated by RT-qPCR. Results are expressed as means +/- SD of copies/ml from an
485 experiment performed in triplicate. (C) Culture media of infected 293T-4R/miR122/apoE
486 cells were harvested 72h post-infection and passaged onto naïve Huh7.5.1 cells that
487 were pre-incubated with either control IgG, DMSO, or with indicated entry inhibitors.
488 Results represent mean percentages of HCV infection (as assessed by luciferase
489 activity) relative to control +/- SD from a representative of two independent experiments
490 performed in triplicate, and 100% relative infectivity is represented by a solid line. Virus
491 used was JcR2a with a TCID₅₀ of 10⁵ to 10⁶/ml. (D) Density distributions of infectious
492 293T-4R/miR122/apoE- and Huh7.5.1-derived HCVcc (Jc1) were determined by

493 overlaying 0.5 ml of culture media on a 5 ml, 4-40% iodixanol step gradient, and
494 ultracentrifuging samples for 16h at 40,000 rpm on a SW-55 rotor (Beckman Coulter).
495 Fractions were carefully harvested from the top of each tube, and density was
496 determined by weighing 0.5 ml of each fraction. Each fraction was assayed for infectivity
497 by TCID₅₀ by detecting NS5A as described (22).

498


499

A.


Loci Tested	AMELO	THO1	D5	D13	D7
ATCC Reference: CRL-1573 (HEK293)	X, X	7, 9.3	8, 9	12, 14	11, 12
293T cells	X, X	9.3, 9.3	8, 9	12, 13, 14	11, 12


Loci Tested	D16	CSF	VWA	TPOX
ATCC Reference: CRL-1573 (HEK293)	9, 13	11, 12	16, 19	11, 11
293T cells	9, 13	11, 12	16, 19	11, 11


B.



C.







505

506

